Clinical trial · no report yet · Phase 1
NCT03829111
CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer
- NCT03829111 ↗
- Completed
- City of Hope Medical Center
- 3 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Pilot Study to Evaluate the Biologic Effect of CBM588 in Combination With Nivolumab/Ipilimumab for Patients With Metastatic Renal Cell Carcinoma
- Phase
- Phase 1
- Status
- Completed
- Conditions
- Advanced Renal Cell Carcinoma; Clear Cell Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Unresectable Renal Cell Carcinoma
- Interventions
- Clostridium butyricum CBM 588 Probiotic Strain; Ipilimumab; Nivolumab
- Arms
- Arm I (nivolumab, ipilimumab) · Active comparator
- Arm II (CBM588, nivolumab, ipilimumab) · Experimental
- Enrollment
- 30
- Primary outcomes
- Change in Bifidobacterium composition of stool
- Sponsor
- City of Hope Medical Center with National Cancer Institute (NCI)
- Start
- May 14, 2019
- Primary completion
- Dec 13, 2023
- Results posted
- No
- Registry record
- NCT03829111 · updated Jul 3, 2024
Publications
linked from the registry- Villemin C, Six A, Neville BA, Lawley TD, Robinson MJ, Bakdash G. The heightened importance of the microbiome in cancer immunotherapy. Trends Immunol. 2023 Jan;44(1):44-59. doi: 10.1016/j.it.2022.11.002. Epub 2022 Dec 1. PubMed 36464584
- Dizman N, Meza L, Bergerot P, Alcantara M, Dorff T, Lyou Y, Frankel P, Cui Y, Mira V, Llamas M, Hsu J, Zengin Z, Salgia N, Salgia S, Malhotra J, Chawla N, Chehrazi-Raffle A, Muddasani R, Gillece J, Reining L, Trent J, Takahashi M, Oka K, Higashi S, Kortylewski M, Highlander SK, Pal SK. Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nat Med. 2022 Apr;28(4):704-712. doi: 10.1038/s41591-022-01694-6. Epub 2022 Feb 28. PubMed 35228755